Sivik Global Healthcare LLC Purchases New Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Sivik Global Healthcare LLC bought a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 4th quarter, HoldingsChannel reports. The fund bought 10,000 shares of the medical research company’s stock, valued at approximately $3,285,000. Bio-Rad Laboratories comprises approximately 1.7% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 26th largest holding.

A number of other large investors also recently modified their holdings of the stock. Principal Financial Group Inc. increased its stake in shares of Bio-Rad Laboratories by 95.6% during the 3rd quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock worth $14,836,000 after purchasing an additional 21,669 shares during the last quarter. Mawer Investment Management Ltd. boosted its position in Bio-Rad Laboratories by 63.0% during the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock worth $72,900,000 after purchasing an additional 84,237 shares during the period. Verition Fund Management LLC increased its stake in shares of Bio-Rad Laboratories by 193.3% in the third quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company’s stock worth $1,161,000 after purchasing an additional 2,287 shares in the last quarter. Diversified Trust Co bought a new stake in shares of Bio-Rad Laboratories in the fourth quarter valued at approximately $958,000. Finally, Louisiana State Employees Retirement System lifted its stake in shares of Bio-Rad Laboratories by 341.7% during the 3rd quarter. Louisiana State Employees Retirement System now owns 5,300 shares of the medical research company’s stock valued at $1,773,000 after buying an additional 4,100 shares in the last quarter. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock opened at $355.00 on Thursday. The firm has a fifty day simple moving average of $339.05 and a two-hundred day simple moving average of $334.46. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a twelve month low of $262.12 and a twelve month high of $387.99. The company has a market capitalization of $9.94 billion, a PE ratio of -12.99 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.16 by $0.85. The firm had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.33 earnings per share. Research analysts expect that Bio-Rad Laboratories, Inc. will post 10.33 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BIO. Citigroup lifted their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Bio-Rad Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $394.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.